Flexion Therapeutics Inc.

8.61-0.1500-1.71%Vol 1.09M1Y Perf -9.09%
Apr 20th, 2021 16:00 DELAYED
BID8.30 ASK8.65
Open8.66 Previous Close8.76
Pre-Market- After-Market8.61
 - -  - -%
Target Price
20.60 
Analyst Rating
Strong Buy 1.25
Potential %
139.26 
Finscreener Ranking
★★★★+     58.74
Insiders Trans % 3/6/12 mo.
-100/-100/-64 
Value Ranking
★★+     50.55
Insiders Value % 3/6/12 mo.
-100/-100/-63 
Growth Ranking
★★★★+     67.85
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-58 
Income Ranking
 —    -
Market Cap429.85M 
Earnings Rating
Strong Buy
Price Range Ratio 52W %
12.29 
Earnings Date
6th May 2021

Today's Price Range

8.478.85

52W Range

7.8014.39

5 Year PE Ratio Range

-5.80-5.10

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-8.11%
1 Month
-15.42%
3 Months
-24.61%
6 Months
-26.97%
1 Year
-9.09%
3 Years
-65.18%
5 Years
-34.38%
10 Years
-

TickerPriceChg.Chg.%
FLXN8.61-0.1500-1.71
AAPL133.11-1.7300-1.28
GOOG2 293.63-8.7700-0.38
MSFT258.26-0.4800-0.19
XOM55.29-1.1900-2.11
WFC42.54-1.3400-3.05
JNJ166.483.79002.33
FB302.650.41000.14
GE13.06-0.4000-2.97
JPM149.27-3.3800-2.21
Financial StrengthValueIndustryS&P 500US Markets
3.70
4.10
0.93
13.73
-4.70
Leverage Ratio 422.40
ProfitabilityValueIndustryS&P 500US Markets
77.50
-129.90
-126.00
-
-
RevenueValueIndustryS&P 500US Markets
65.43M
1.31
222.70
-
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.44-0.409.09
Q03 2020-0.49-0.50-2.04
Q02 2020-0.70-0.76-8.57
Q01 2020-1.04-0.958.65
Q04 2019-1.01-0.8812.87
Q03 2019-1.01-1.000.99
Q02 2019-1.06-0.969.43
Q01 2019-1.13-1.093.54
Earnings Per EndEstimateRevision %Trend
3/2021 QR-0.4914.04Positive
6/2021 QR-0.50-8.70Negative
12/2021 FY-1.90-15.85Negative
12/2022 FY-0.68-88.89Negative
Next Report Date6th May 2021
Estimated EPS Next Report-0.49
Estimates Count4
EPS Growth Next 5 Years %20.00
Volume Overview
Volume1.09M
Shares Outstanding49.92M
Trades Count6.77K
Dollar Volume8.78M
Avg. Volume823.15K
Avg. Weekly Volume1.14M
Avg. Monthly Volume1.14M
Avg. Quarterly Volume869.43K

Flexion Therapeutics Inc. (NASDAQ: FLXN) stock closed at 8.61 per share at the end of the most recent trading day (a -1.71% change compared to the prior day closing price) with a volume of 1.09M shares and market capitalization of 429.85M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 288 people. Flexion Therapeutics Inc. CEO is Michael D. Clayman.

The one-year performance of Flexion Therapeutics Inc. stock is -9.09%, while year-to-date (YTD) performance is -25.39%. FLXN stock has a five-year performance of -34.38%. Its 52-week range is between 7.8 and 14.39, which gives FLXN stock a 52-week price range ratio of 12.29%

Flexion Therapeutics Inc. currently has a PE ratio of -3.60, a price-to-book (PB) ratio of 38.72, a price-to-sale (PS) ratio of 7.18, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -46.53%, a ROC of -50.49% and a ROE of 589.88%. The company’s profit margin is -%, its EBITDA margin is -126.00%, and its revenue ttm is $65.43 Million , which makes it $1.31 revenue per share.

Of the last four earnings reports from Flexion Therapeutics Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.49 for the next earnings report. Flexion Therapeutics Inc.’s next earnings report date is 06th May 2021.

The consensus rating of Wall Street analysts for Flexion Therapeutics Inc. is Strong Buy (1.25), with a target price of $20.6, which is +139.26% compared to the current price. The earnings rating for Flexion Therapeutics Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Flexion Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Flexion Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 7.89, ATR14 : 0.71, CCI20 : -6.47, Chaikin Money Flow : -0.12, MACD : -0.69, Money Flow Index : 57.75, ROC : -2.12, RSI : 53.91, STOCH (14,3) : 49.23, STOCH RSI : 0.16, UO : 52.88, Williams %R : -50.77), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Flexion Therapeutics Inc. in the last 12-months were: Adam Muzikant (Sold 4 005 shares of value $44 576 ), Alan W. Milinazzo (Option Excercise at a value of $40 500), Christina Willwerth (Sold 6 602 shares of value $73 480 ), David A. Arkowitz (Sold 8 486 shares of value $93 846 ), Kerry Wentworth (Sold 6 829 shares of value $76 007 ), Mark S. Levine (Sold 6 829 shares of value $76 007 ), Mark Stejbach (Buy at a value of $19 997), Melissa Layman (Sold 7 144 shares of value $86 267 ), Michael D. Clayman (Buy at a value of $99 996), Scott D. Kelley (Sold 6 829 shares of value $76 007 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
6 (75.00 %)
5 (71.43 %)
5 (100.00 %)
Moderate Buy
2 (25.00 %)
2 (28.57 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.25
Strong Buy
1.29
Strong Buy
1.00

Flexion Therapeutics Inc.

Flexion Therapeutics Inc is a United States-based specialty pharmaceutical company. The company focuses on the development and commercialization of novel, local therapies. The company specializes in the treatment of patients with musculoskeletal conditions beginning with osteoarthritis. The products offered by company are zilretta which is used for enhancing clinical effect of intra articular corticosteroid treatment.

CEO: Michael D. Clayman

Telephone: +1 781 305-7777

Address: 10 Mall Road, Burlington 01803, MA, US

Number of employees: 288

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

62%38%

Bearish Bullish

52%48%

Bearish Bullish

50%50%

News

Stocktwits